Fortis Inc. closed 2.6% below its 52-week high of C$64.39, which the company reached on February 14th.
In a report released yesterday, Maurice Choy from RBC Capital maintained a Hold rating on Fortis (FTS – Research Report), with a price target ...
Wells Fargo analyst Neil Kalton maintained a Hold rating on Fortis (FTS – Research Report) on February 14 and set a price target of C$66.00.
Fortis Inc. closed 2.9% short of its 52-week high of C$64.39, which the company achieved on February 14th.
Healthcare services provider Fortis Healthcare Ltd is set to acquire Jalandhar-based Shrimann Superspeciality Hospital in a Rs 462-crore ($53.2 million) deal. The all-cash deal will help Fortis ...
(RTTNews) - Fortis Inc. (FTS.TO) revealed a profit for its fourth quarter that increased from the same period last year and beat the Street estimates. The company's earnings totaled C$396 million ...
There’s no doubt that one of the best stocks you can buy on the TSX both for reliability and dividend income is Fortis (TSX:FTS), the $31 billion utility stock. It’s no secret that the utility ...
The year ahead looks good for Fortis stock, as the company ramps up its spending amidst the possibility of new opportunities. Throughout its history, Fortis stock has been a reliable source of ...
Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation ® technology and ExPERT â„¢ platform.
Leading companies like Novartis, Merck, and Bristol Myers Squibb are spearheading advancements, redefining patient treatment possibilities. < ...
RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2025 /PRNewswire/ -- Dignify Therapeutics, a biotechnology company dedicated to restoring voluntary bowel and bladder function in patients with neurological ...
Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...